Business Context and Reporting Period
This Form 8-K Current Report was filed by aTyr Pharma, Inc. on May 21, 2021. The filing reports a corporate governance event: the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel appointment and does not contain financial statement data.
Material Changes
The material change reported is the appointment of Sara L. Zaknoen, M.D. to the Board of Directors, effective May 21, 2021. Dr. Zaknoen was appointed as a Class I director, serving until the 2022 annual meeting of stockholders or until a successor is elected.
Compensation and Governance Details
- Compensation: Dr. Zaknoen will receive cash and equity compensation under the Company's standard non-employee director policy.
- Equity Grant: She was granted an option to purchase 2,285 shares of Common Stock. The exercise price equals the closing price on May 21, 2021.
- Vesting Schedule: The option vests in equal monthly installments over three years, contingent on continued service.
- Agreements: Dr. Zaknoen entered into the Company's standard indemnification agreement. No other transactions requiring Item 404(a) disclosure exist.
Investor Verification Checklist
- Verify the closing stock price on May 21, 2021, to determine the exercise price of the granted options.
- Review the 2021 Proxy Statement (filed March 24, 2021) for details on the non-employee director cash compensation policy.
- Confirm Dr. Zaknoen's continued service status to track option vesting progress.
- Check for any subsequent filings regarding the 2022 annual meeting to confirm the director's term status.